Combination Therapy Significantly Extends Life for Patients With Severe Heart Disease

September 17, 2026 aortic stenosis, cardiac amyloidosis, tafamidis

A recent international study has revealed that pairing heart valve replacement surgery with targeted drug therapy can deliver a profound survival advantage for older adults suffering from a dangerous combination of cardiac conditions. Published in the European Heart Journal, the findings focus on patients dealing with both aortic stenosis and concomitant cardiac amyloidosis, a pairing long associated with an elevated risk of mortality.

Aortic stenosis involves the narrowing of the aortic valve, which restricts blood flow from the left ventricle into the broader circulatory system. Cardiac amyloidosis occurs when misfolded proteins accumulate within the heart muscle, impairing the organ’s overall pumping capacity. Both conditions frequently co-exist in older populations. Traditionally, clinical management has focused primarily on replacing the narrowed valve via surgery, while the underlying protein deposits in the heart muscle were frequently left unaddressed.

To evaluate whether treating both issues concurrently could improve outcomes, an international research consortium led by the Medical University of Vienna and University College London analyzed data from 226 patients across ten different countries. The research team, spearheaded by lead investigator Christian Nitsche from MedUni Vienna’s Department of Medicine II and Thomas Treibel from University College London’s Department of Cardiovascular Imaging, sought to understand the impact of comprehensive intervention.

The resulting analysis demonstrated that both mechanical valve replacement and medical management of amyloidosis using the targeted drug tafamidis independently correlated with a significantly reduced risk of death. Crucially, the survival benefit reached its peak among patients who underwent both forms of treatment simultaneously. According to Nitsche, the long-term survival rates for individuals receiving the dual intervention closely mirrored those of aortic stenosis patients who did not have amyloidosis at all.

Both medical issues place severe mechanical and functional stress on the heart. While valve surgery relieves the pressure caused by the obstructed pathway, targeted pharmacological therapy works to slow the progression of the protein deposits. Despite affecting roughly ten percent of individuals diagnosed with aortic stenosis, cardiac amyloidosis frequently goes unrecognized during routine clinical evaluations.

Given these insights, the research team advocates for routine screening among patients presenting with severe aortic valve narrowing. Identifying co-existing amyloidosis early allows clinicians to deploy life-prolonging combination therapies that can fundamentally alter the disease course and improve long-term prognosis for elderly patients.

Key Takeaways for Clinical Practice

Dual therapy combining valve replacement and tafamidis significantly lowers mortality risk.
Patients receiving both treatments demonstrated long-term survival rates comparable to those with isolated aortic stenosis.
Researchers recommend proactive screening for cardiac amyloidosis in all patients diagnosed with severe aortic valve narrowing.

Source: ScienceDaily Health & Medicine